Cyclosporine市場機會、成長要素、產業趨勢分析及2026-2035年預測

2025 年全球Cyclosporine市場價值為 38 億美元，預計到 2035 年將達到 147 億美元，年複合成長率為 14.8%。

類風濕性關節炎和銀屑病等自體免疫疾病的日益流行是Cyclosporine需求的主要促進因素，而新興國家醫療保健覆蓋範圍的擴大和免疫抑制療法研究投入的增加也支撐著市場成長。此外，器官捐贈意識的提高、移植技術的進步以及免疫抑制療法的日益普及，都促進了全球市場的穩定擴張。Cyclosporine在預防器官排斥和治療慢性自體免疫疾病方面的有效性日益受到認可，這促使其在全球各地的醫院、門診診所和專科醫療中心得到更廣泛的應用。

Cyclosporine是一種免疫抑制劑，主要用於預防器官移植患者的排斥反應以及治療自體免疫疾病。它的作用機轉是抑制T淋巴細胞（免疫系統的關鍵組成部分）的活性，從而防止T淋巴細胞攻擊移植器官或健康組織。此藥物常用於腎臟、肝臟或心臟移植患者，以及類風濕性關節炎、乾癬和某些眼部疾病等自體免疫疾病患者。自體免疫疾病（免疫系統攻擊健康細胞並引起發炎）發病率的不斷上升，導致對Cyclosporine等有效治療方法的需求日益成長。

預計到2025年，器官移植排斥預防市場規模將達14億美元。該市場佔據主導地位的原因在於Cyclosporine在預防器官移植後排斥反應方面發揮的關鍵作用。腎臟、肝臟和心臟移植手術數量的不斷增加，以及手術技術和術後護理的創新，進一步提升了對可靠預防性治療的需求，使該市場成為重要的收入來源。

預計到2025年，膠囊劑市佔率將達到31.7%。這主要歸功於膠囊劑能夠提高患者在移植和自體免疫疾病治療等長期治療中的遵守用藥。膠囊技術的進步提高了Cyclosporine的生物利用度和穩定性，進一步鞏固了該細分市場的地位。需要免疫抑制治療的慢性疾病盛行率不斷上升，以及非專利藥的上市，都強化了膠囊劑在市場上的主導地位。

預計到2025年，北美Cyclosporine市佔率將達到36.8%，並在整個預測期內保持強勁成長。這一市場主導地位得益於移植和眼科領域強勁的臨床需求、較高的眼表疾病發病率以及先進的醫療基礎設施。完善的保險報銷機制和大量的手術量進一步鞏固了北美在Cyclosporine市場的主導地位，使該地區成為全球環孢素收入的主要來源。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章業界考察

• 生態系分析
• 影響產業的因素
  • 促進因素
    • 自體免疫疾病盛行率增加
    • 器官移植手術數量不斷增加
    • 眼科適應症的擴大
    • 擴大學名藥的取得途徑
  • 產業潛在風險與挑戰
    • 有害的副作用
    • 替代免疫抑制劑的可用性
  • 市場機遇
    • 眼科領域管線和適應症的擴展
    • 進入新興市場
• 成長潛力分析
• 監理情勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
• 臨床試驗和研發管線分析（基於初步調查）
• 價格分析（基於初步調查）
• 還款方案（基於初步調查）
• 人工智慧和生成式人工智慧對市場的影響
• 波特五力分析
• PESTEL 分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 北美洲
  • 歐洲
  • 亞太地區
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 合作夥伴關係和合資企業
  • 新產品發布
  • 業務拓展計劃

第5章 市場估計與預測：依應用領域分類，2022-2035年

• 預防移植排斥反應
• 類風濕性關節炎
• 銀屑病
• 自體免疫重症肌無力
• 乾眼症
• 其他跡象

第6章 市場估計與預測：依劑型分類，2022-2035年

• 膠囊
• 眼藥水
• 解決方案
• 乳膏和軟膏

第7章 市場估計與預測：依給藥途徑分類，2022-2035年

• 口服
• 外用
• 腸外

第8章 市場估算與預測：依通路分類，2022-2035年

• 醫院藥房
• 零售藥房
• 網路藥房

第9章 市場估計與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Amneal Pharmaceuticals
• Avet Pharmaceuticals
• AdvaCare Pharma
• AbbVie
• Apotex
• Bora Pharmaceuticals
• Cipla
• Dr. Reddy's Laboratories
• Novartis
• Santen Pharmaceutical
• Sun Pharmaceutical Industries
• Strides Pharma Science Limited
• Teva Pharmaceutical Industries
• Viatris

The Global Cyclosporine Market was valued at USD 3.8 billion in 2025 and is estimated to grow at a CAGR of 14.8% to reach USD 14.7 billion by 2035.

The rising prevalence of autoimmune disorders, including rheumatoid arthritis and psoriasis, is a primary driver for cyclosporine demand, while expanding healthcare access in emerging economies and growing investment in immunosuppressive therapy research support market growth. Additionally, heightened awareness of organ donation, advancements in transplant technology, and increasing adoption of immunosuppressive therapies contribute to the steady expansion of the global market. Cyclosporine is increasingly recognized for its effectiveness in preventing organ rejection and managing chronic autoimmune conditions, further enhancing its adoption across hospitals, outpatient clinics, and specialty care centers worldwide.

Cyclosporine is an immunosuppressive medication that primarily prevents organ rejection in transplant recipients and manages autoimmune diseases. It works by inhibiting T-lymphocyte activity, a central component of the immune system, thereby preventing attacks on transplanted organs or healthy tissue. The drug is prescribed for patients undergoing kidney, liver, or heart transplants and for autoimmune conditions such as rheumatoid arthritis, psoriasis, and specific ophthalmic disorders. The growing incidence of autoimmune diseases, which result from the immune system attacking healthy cells and causing inflammation, has created a strong demand for effective therapies like cyclosporine.

The transplant rejection prophylaxis segment reached USD 1.4 billion in 2025. Its dominance is driven by the crucial role cyclosporine plays in preventing post-transplant organ rejection. High transplant volumes, including kidney, liver, and heart procedures, along with innovations in surgical techniques and post-operative care, have further boosted demand for reliable prophylactic treatments, making this segment a major revenue contributor.

The capsule segment held a share of 31.7% in 2025, as capsules offer superior patient compliance for long-term therapies required in transplant and autoimmune treatments. Advances in encapsulation technology enhance cyclosporine's bioavailability and stability, further strengthening this segment. The rising prevalence of chronic diseases requiring immunosuppressive therapy, coupled with the availability of generic formulations, has cemented the capsule segment's leadership position in the market.

North America Cyclosporine Market captured 36.8% share in 2025 and is expected to witness robust growth during the forecast period. This dominance is supported by strong clinical demand for transplant and ophthalmology indications, high rates of ocular surface disorders, and advanced healthcare infrastructure. Comprehensive reimbursement coverage and high procedure volumes further reinforce North America's leadership in the cyclosporine market, making the region a key revenue contributor globally.

Major players operating in the Global Cyclosporine Market include Amneal Pharmaceuticals, Avet Pharmaceuticals, AdvaCare Pharma, AbbVie, Apotex, Bora Pharmaceuticals, Cipla, Dr. Reddy's Laboratories, Novartis, Santen Pharmaceutical, Sun Pharmaceutical Industries, Strides Pharma Science Limited, Teva Pharmaceutical Industries, and Viatris. Companies in the Cyclosporine Market are adopting strategies such as expanding their product portfolios to include novel formulations with improved bioavailability, stability, and patient compliance. Firms are investing in research and development for new immunosuppressive therapies and exploring combination therapies to strengthen clinical efficacy. Geographic expansion into emerging markets with growing transplant programs and autoimmune disease prevalence is a key focus. Strategic partnerships with hospitals, clinics, and distribution networks enhance market penetration. Additionally, generic product launches, pricing strategies, and awareness campaigns for transplant and autoimmune care improve brand recognition and adoption rates, helping companies maintain a competitive edge and sustain long-term growth in the cyclosporine market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Indication trends
  • 2.2.3 Dosage form trends
  • 2.2.4 Route of administration trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of autoimmune diseases
    • 3.2.1.2 Growing organ transplantation procedures
    • 3.2.1.3 Expansion of ophthalmic indications
    • 3.2.1.4 Growing access to generic products
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse side effects
    • 3.2.2.2 Availability of alternative immunosuppressants
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion in the ophthalmology pipeline and indications
    • 3.2.3.2 Emerging market penetration
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Clinical trials and pipeline analysis (Driven by primary research)
• 3.6 Pricing analysis (Driven by primary research)
• 3.7 Reimbursement scenario (Driven by primary research)
• 3.8 Impact of AI and generative AI on the market
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 North America
  • 4.2.2 Europe
  • 4.2.3 Asia Pacific
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Indication, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Transplant rejection prophylaxis
• 5.3 Rheumatoid arthritis
• 5.4 Psoriasis
• 5.5 Autoimmune myasthenia gravis
• 5.6 Dry eye
• 5.7 Other indications

Chapter 6 Market Estimates and Forecast, By Dosage Form, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Capsule
• 6.3 Eye drops
• 6.4 Solutions
• 6.5 Creams and ointments

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Topical
• 7.4 Parenteral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Amneal Pharmaceuticals
• 10.2 Avet Pharmaceuticals
• 10.3 AdvaCare Pharma
• 10.4 AbbVie
• 10.5 Apotex
• 10.6 Bora Pharmaceuticals
• 10.7 Cipla
• 10.8 Dr. Reddy's Laboratories
• 10.9 Novartis
• 10.10 Santen Pharmaceutical
• 10.11 Sun Pharmaceutical Industries
• 10.12 Strides Pharma Science Limited
• 10.13 Teva Pharmaceutical Industries
• 10.14 Viatris